Literature DB >> 20569048

Follistatin as a potent regulator of bone metabolism.

A Gajos-Michniewicz1, A W Piastowska, J A Russell, T Ochedalski.   

Abstract

Follistatin is a monomeric glycoprotein, distributed in a wide range of tissues. Recent work has demonstrated that this protein is a pluripotential molecule that has no structural similarity but is functionally associated with members of the transforming growth factor (TGF)-β superfamily, which indicates its wide range of action. Members of the TGF-β superfamily, especially activins and bone morphogenetic proteins are involved in bone metabolism. They play an important role in bone physiology, influencing bone growth, turnover, bone formation and cartilage induction. As follistatin is considered to be the antagonist of the TGF-β superfamily members, it plays an important role in bone metabolism and development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20569048     DOI: 10.3109/1354750X.2010.495786

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  12 in total

1.  Circulating follistatin in patients with chronic kidney disease: implications for muscle strength, bone mineral density, inflammation, and survival.

Authors:  Tetsu Miyamoto; Juan Jesús Carrero; Abdul Rashid Qureshi; Björn Anderstam; Olof Heimbürger; Peter Bárány; Bengt Lindholm; Peter Stenvinkel
Journal:  Clin J Am Soc Nephrol       Date:  2011-02-24       Impact factor: 8.237

Review 2.  Clinical and Therapeutic Implications of Follistatin in Solid Tumours.

Authors:  Lei Shi; Jeyna Resaul; Sioned Owen; Lin Ye; Wen G Jiang
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

Review 3.  Modulators of erythropoiesis: emerging therapies for hemoglobinopathies and disorders of red cell production.

Authors:  Laura Breda; Stefano Rivella
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

Review 4.  Follistatin as potential therapeutic target in prostate cancer.

Authors:  Maria Vittoria Sepporta; Francesca Maria Tumminello; Carla Flandina; Marilena Crescimanno; Marco Giammanco; Maurizio La Guardia; Danila di Majo; Gaetano Leto
Journal:  Target Oncol       Date:  2013-03-01       Impact factor: 4.493

Review 5.  Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular Dystrophy.

Authors:  Antoine Boulanger Piette; Dounia Hamoudi; Laetitia Marcadet; Françoise Morin; Anteneh Argaw; Leanne Ward; Jérôme Frenette
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

6.  Mid-gestational gene expression profile in placenta and link to pregnancy complications.

Authors:  Liis Uusküla; Jaana Männik; Kristiina Rull; Ave Minajeva; Sulev Kõks; Pille Vaas; Pille Teesalu; Jüri Reimand; Maris Laan
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

Review 7.  TGF-β and BMP signaling in osteoblast differentiation and bone formation.

Authors:  Guiqian Chen; Chuxia Deng; Yi-Ping Li
Journal:  Int J Biol Sci       Date:  2012-01-21       Impact factor: 6.580

8.  RUNX3, EGR1 and SOX9B form a regulatory cascade required to modulate BMP-signaling during cranial cartilage development in zebrafish.

Authors:  Julia Dalcq; Vincent Pasque; Aurélie Ghaye; Arnaud Larbuisson; Patrick Motte; Joseph A Martial; Marc Muller
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240

9.  Myostatin and insulin-like growth factor I: potential therapeutic biomarkers for pompe disease.

Authors:  Yin-Hsiu Chien; Der-Sheng Han; Wuh-Liang Hwu; Beth L Thurberg; Wei-Shiung Yang
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

10.  Serum Levels of Follistatin Are Positively Associated With Serum-Free Thyroxine Levels in Patients With Hyperthyroidism or Euthyroidism.

Authors:  Fen-Yu Tseng; Yen-Ting Chen; Yu-Chao Chi; Pei-Lung Chen; Wei-Shiung Yang
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.